Recent improvements in high-throughput proteomic approaches are likely to constitute an
essential advance in biomarker discovery, holding promise for improved personalized care …

Schizophrenia is a psychiatric illness that affects approximately 30 million people worldwide.
Converging lines of evidence suggest that mitochondrial function may be compromised in …

Increased peripheral levels of morning cortisol have been reported in people with
schizophrenia (SZ) and bipolar disorder (BD), but findings are inconsistent and few studies …

Major depressive disorder (MDD) is a widespread and debilitating mental disorder.
However, there are no biomarkers available to aid in the diagnosis of this disorder. In this …

Recently, we showed that the circulating levels of insulin-related peptides and the secretory
granule protein chromogranin A were increased in small cohorts of first onset schizophrenia …

Despite decades of research, the pathophysiology and aetiology of schizophrenia remains
incompletely understood. The disorder is frequently accompanied by metabolic symptoms …

Little is known about the biological mechanisms underpinning the pathology of
schizophrenia. We have analysed the proteome of stimulated and unstimulated peripheral …

Most proteomic studies to date have attempted to identify changes in protein levels without
considering the effects of post-translational modifications (PTM). However, characteristic …

Over a century, a wide-ranging variety of pathophysiological models and causal hypotheses
have been conceptualized for schizophrenia. One among these is the role for free radical …

Objectives Understanding the biological process and progression of schizophrenia is the
first step to developing novel approaches and new interventions. Research on new …